The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.
The clinical trial using MAF capsules has started in Ukraine from the end of October for hospitalised patients with COVID-19.
-FAKE PRODUCTS WARNING-
3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.
Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.
Keihan Clinic, Kobe Clinic and Science Clinic Cancer treatments, Science Clinic Skin Beauty treatments will be closed from Wednesday 30th December 2020 until Monday 4th January 2021.
We will reopen for business in the new year on Tuesday 5th January 2021.
This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.
Developed by Saisei Mirai and Tokushima University in 2014.
• GcMAF produced from bovine colostrum.
• 1mg capsule has equivalent activity to 100ng purified GcMAF.
• Enteric acid-resistant capsule for oral administration, powder for sublingual
• Target Payer‘s Patches/GUT and Waldeyer’s tonsillar ring.
• New patents pending production process
• Permitted as a food product in Japan
・Low stability at room temperature
・Chemically isolated (purified), sterilization process using 0.22 μm filtration system
・25-(OH) Vitamin D3 Affinity Column
・Affinity column has cross-contamination risk when used repeatedly; must be disposable
Cancer treatments / Skin rejuvenation treatments
Cancer treatments / Immunotherapy
Skin Beauty treatments
Saisei Mirai immunotherapy laboratory for the production of GcMAF,
Hyper T/NK cells, lymphocytes and other immunotherapies.
This site is for our patients and medical personnel.
– Cancer treatments
– Skin Beauty treatments
Osaka Cell Processing Center
We offer Cancer immunotherapy treatments and Skin rejuvenation treatments.
We are working on the treatment of Cancer and Immunotherapy. We will offer our treatments to more patients.
– Cancer treatments
We are working on the treatment of Cancer and Immunotherapy.
-Skin Beauty treatments
It is specialized for Total Aging-Care, Anti-Aging.
Saisei Mirai immunotherapy laboratory for the production of GcMAF, Hyper T/NK cells, lymphocytes and other immunotherapies.